Liquidia Corp 8-K: Officer Compensation Arrangements Updated

TL;DR

**Liquidia Corp just updated executive pay, watch for impact on financials and talent retention.**

AI Summary

Liquidia Corp filed an 8-K on January 19, 2024, reporting an event on January 15, 2024, related to changes in compensatory arrangements for certain officers. This filing indicates that the company is actively managing its executive compensation, which can impact its financial health and ability to retain key talent. For investors, understanding these arrangements is crucial as they directly affect operational costs and potentially the company's long-term stability and performance.

Why It Matters

Changes in executive compensation can signal shifts in company strategy or financial health, directly influencing investor confidence and the stock's perceived value.

Risk Assessment

Risk Level: low — This filing is routine and reports on compensatory arrangements, which is a standard corporate governance item and does not inherently pose a high risk.

Analyst Insight

A smart investor would monitor subsequent filings or press releases for specific details regarding the compensatory arrangements, as this 8-K only broadly indicates changes without providing specifics. This could impact future financial performance and executive retention.

Key Players & Entities

• Liquidia Corp (company) — the registrant filing the 8-K
• January 15, 2024 (date) — date of the earliest event reported
• January 19, 2024 (date) — date the 8-K was filed
• 001-39724 (other) — Commission File Number
• LQDA (other) — Trading Symbol for Common stock

FAQ

Key Financial Figures

• $575,000 — . Kaseta's base salary will increase to $575,000 from $521,144 per year, effective as of
• $521,144 — e salary will increase to $575,000 from $521,144 per year, effective as of the Effective

Filing Documents

• tm243606d1_8k.htm (8-K) — 30KB
• tm243606d1_ex99-1.htm (EX-99.1) — 11KB
• 0001104659-24-005009.txt ( ) — 217KB
• lqda-20240115.xsd (EX-101.SCH) — 3KB
• lqda-20240115_lab.xml (EX-101.LAB) — 33KB
• lqda-20240115_pre.xml (EX-101.PRE) — 22KB
• tm243606d1_8k_htm.xml (XML) — 3KB

02 Departure Of Directors

Item 5.02 Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers. Termination of Chief Operations Officer On January 15, 2024, Liquidia Corporation, a Delaware corporation (the "Company") terminated Robert Lippe from his position as the Chief Operations Officer of the Company. Mr. Lippe will continue his employment with the Company on an at-will basis for a transition period ending April 15, 2024. At the end of this transition period, and subject to his execution of a separation agreement and general release (the "Separation Agreement") with Liquidia Technologies, Inc., a wholly owned subsidiary of the Company, Mr. Lippe would then be eligible to receive an amount equal to his then current base salary for nine (9) months (the "Severance Payments"), less all applicable withholdings and deductions, as and to the extent set forth in his Amended and Restated Employment Agreement, dated July 25, 2018. In accordance with applicable law, Mr. Lippe may revoke the general release at any time during the seven days following his execution of the general release in which case he will not be entitled to the Severance Payments. Appointment of New Chief Operating Officer On January 15, 2024 (the "Effective Date"), the Company promoted Michael Kaseta, the current Chief Financial Officer ("CFO") of the Company, to the role of Chief Operating Officer (the "COO"), effective immediately. As of the Effective Date, Mr. Kaseta will serve as both the CFO and COO of the Company. Mr. Kaseta, age 48, has served as the Company's CFO since November 2020. Prior to joining the Company, Mr. Kaseta served as CFO of Aerami Therapeutics, Inc., a private biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension, from January 2019 until November 2020, and served as CFO of Aralez Pharmaceuticals Inc., a form

01 Other Events

Item 8.01 Other Events. On January 19, 2024, the Company issued a press release announcing the promotion of Mr. Kaseta to COO. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit 99.1 Press Release of Liquidia Corporation, dated January 19, 2024. 104 Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. January 19, 2024 Liquidia Corporation By: /s/ Roger Jeffs Name: Roger Jeffs Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR